Nanoscope Therapeutics Publishes Breakthrough Research on Gene Therapy for Vision Restoration
Nanoscope Therapeutics Inc., a biotech company developing gene therapies for retinal degenerative diseases, has published new research in Advanced Therapeutics, part of Wiley’s renowned Advanced journal portfolio. The peer-reviewed paper, titled “Topology and Mechanism of Broadband and Fast Multi-Characteristic Opsin (MCO) for Neuromodulation,” details the structure and function of Nanoscope’s proprietary MCO platform. Using predictive protein modeling, molecular assays, and electrophysiology, the study highlights MCO’s unique ability to activate retinal cells using ambient light. Key findings demonstrate that MCO-010, the company’s lead therapeutic candidate, enables fast, sensitive, and broad-spectrum light activation—supporting its potential as a best-in-class treatment for patients with vision loss caused by retinal degeneration.
Nanoscope Therapeutics Publishes Breakthrough Research on Gene Therapy for Vision Restoration